Self-Management and Glycemic Control in Adult Haitian Immigrants With Type 2 Diabetes

July 21, 2025 updated by: New York University

Self-Management and Glycemic Control in Adult Haitian Immigrants With Type 2 Diabetes: A Pilot Randomized Study

The objective of the study is to conduct a pilot randomized study to test feasibility and preliminary efficacy of the developed diabetes self-management education program with 40 adult Haitian immigrants.

Study Overview

Detailed Description

This is a two-arm randomized trial. Participants will be randomized to the culturally tailored Diabetes Self-Management Education Program or standard care condition in a 1:1 allocation. All participants will receive standard type 2 diabetes care at the enrolled clinic and remain under their providers' care for the duration of the study. The culturally tailored Diabetes Education Program involves the following: 1) an initial 45-minute face-to-face consultation; and 2) six 2-hour weekly interactive educational sessions in a format to be determined (TBD) by Aim 1 (e.g., in-person, video/telephone conference call).

Study Type

Interventional

Enrollment (Estimated)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • New York
      • New York, New York, United States, 10010
        • New York University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 90 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Self-described Haitian immigrant aged 21 and older
  • Known diagnosis of type 2 diabetes for at least one year
  • Have lived in the US for at least one year
  • Have an HbA1c of 7.5%
  • Willing and able to participate in an individual interview

Exclusion Criteria:

  • Having a diagnosis of type 1 diabetes
  • Unable to comprehend, consent and or fully participate in the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Diabetes Self-Management Behaviors
Self-Management Education Program The culturally tailored Diabetes Self-Management Education Program involves the following: 1) an initial 45-minute face-to-face private consultation collaboratively determining goals; followed by 2) six 2-hour weekly educational interactive sessions in a format TBD by aim 1. We will deliver culturally targeted written materials and presentations in these sessions. Participants will be asked to practice self-management behaviors concurrently and for four additional weeks.
The intervention is to be delivered by an interventionist.
No Intervention: Usual Type 2 Diabetes Care
The usual care arm will receive the clinic's standard type 2 diabetes care and remain under their providers' care for the duration of the study.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Summary of Diabetes of Self-Care Activities Scale (11- item)
Time Frame: (T0) baseline through (T3) 90 days post-intervention
Change in diabetes self-management behaviors (0-7, higher scores indicate improvement)
(T0) baseline through (T3) 90 days post-intervention
Stanford Diabetes Self-Efficacy Scale (8- item)
Time Frame: (T0) baseline through (T3) 90 days post-intervention
Change in general self-efficacy 1-10, higher scores indicate improvement)
(T0) baseline through (T3) 90 days post-intervention
Wrist-worn actigraphy (ActiGraph) to be worn while awake
Time Frame: (T0) baseline through (T3) 90 days post-intervention
Change in physical activity (Frequent physical activity indicates improvement)
(T0) baseline through (T3) 90 days post-intervention
Glucose Variability data from continuous glucose monitor (CGM) will be downloaded directly from participants provided (blinded) FreeStyle Libre Pro
Time Frame: (T0) baseline through (T3) 90 days post-intervention
Time in range and glucose variability (More time in range and less glucose variability indicates improvement)
(T0) baseline through (T3) 90 days post-intervention

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Diabetes Distress Scale (DDS) (17-item), using Numerical Rating Scale: 0-6
Time Frame: (T0) baseline through (T3) 90 days post-intervention
Change in diabetes distress ( 0-6, lower scores indicates improvement)
(T0) baseline through (T3) 90 days post-intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Cherlie Magny-Normilus, PhD, FNP-BC, FAAN, New York University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 12, 2023

Primary Completion (Estimated)

December 31, 2025

Study Completion (Estimated)

December 31, 2025

Study Registration Dates

First Submitted

June 25, 2021

First Submitted That Met QC Criteria

July 1, 2021

First Posted (Actual)

July 2, 2021

Study Record Updates

Last Update Posted (Actual)

July 22, 2025

Last Update Submitted That Met QC Criteria

July 21, 2025

Last Verified

October 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabetes Mellitus, Type 2

Clinical Trials on Diabetes Self-Management Behaviors

Subscribe